Compare Vertex Pharmaceuticals Incorporated (VRTX) vs Zeta Global Holdings Corp (ZETA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vertex Pharmaceuticals Incorporated vs Zeta Global Holdings Corp — how do they compare? Vertex Pharmaceuticals Incorporated trades at $509.67 (market cap $127.55B), while Zeta Global Holdings Corp trades at $33.45 (market cap $8.29B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 15.4× Zeta Global Holdings Corp's market cap, and Zeta Global Holdings Corp is trading nearer its 52-week high, Vertex Pharmaceuticals Incorporated nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Vertex Pharmaceuticals Incorporated for 120 Days and Zeta Global Holdings Corp for 18 Days on average.
| VRTX | ZETA | |
|---|---|---|
Market Cap | $127.55B | $8.29B |
Volume | 1,487,944 | 7,156,795 |
Sector | Health | Technology |
52-Week High | $557.96 | $33.74 |
52-Week Low | $407.37 | $14.55 |
Typical Hold Time | 120 Days | 18 Days |
Enterprise Value | $121.68B | $8.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains strong fundamentals with $12B revenue, 35% net margin, and robust cash flow. Recent positive Phase 2b data for kidney drug inaxaplin and cystic fibrosis dominance support growth. Earnings show volatility with Q1 beat but Q2 miss against expectations.
Outlook remains positive with 84% analyst buy ratings and $573.50 consensus target offering 13% upside. Key risks include clinical trial outcomes, competitive pressures, and reliance on cystic fibrosis portfolio. The stock presents growth potential through pipeline expansion but faces sector volatility and execution challenges.
ZETA trades at $33.74, showing strong technical momentum with a bullish moving average signal and trading near resistance at $34. The company demonstrates solid revenue growth with Q2 2026 revenue reaching $1.6B and has beaten earnings estimates for three consecutive quarters. Recent expansion into the UK market and AI platform adoption are driving investor optimism, though negative net margins and high valuation multiples warrant caution.
ZETA presents a growth opportunity with strong analyst support (75% buy ratings) and AI-driven business expansion, but faces execution risks from negative profitability and elevated valuation metrics. The stock's current price above the $32.40 consensus target suggests near-term consolidation potential amid ongoing business transformation efforts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →About Zeta Global Holdings Corp
Zeta Global is a leading data-driven marketing technology company that provides an omnichannel AI Marketing Cloud. By leveraging a proprietary data cloud of over 2.4 billion deterministic identities, it enables enterprise brands to acquire, grow, and retain customers through predictive intelligence and automated, agentic workflows.
Read more on ZETA →
